New drug duo tested for blood cancer patients out of options

NCT ID NCT01592370

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and early effectiveness of combining two immunotherapy drugs, nivolumab and daratumumab, for people with multiple myeloma that has returned or stopped responding to standard treatments. It involved about 320 participants with various blood cancers, focusing on those who had already tried several other therapies. The main goal was to understand the side effects of this new combination treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Division Of Hematology & Oncology Ctr. For Health Sciences

Los Angeles, California, 90095, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Huntsman Cancer Institute At The Univ. Of Utah

Salt Lake City, Utah, 84112, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Local Institution

Yvoir, B-5530, Belgium
Local Institution

Bologna, 40138, Italy
Local Institution

Chorzów, 41-500, Poland
Local Institution - 0001

New York, New York, 10065, United States
Local Institution - 0002

Rochester, Minnesota, 55905, United States
Local Institution - 0003

Baltimore, Maryland, 21231, United States
Local Institution - 0004

Philadelphia, Pennsylvania, 19111, United States
Local Institution - 0005

Salt Lake City, Utah, 84112, United States
Local Institution - 0006

Portland, Oregon, 97239, United States
Local Institution - 0007

Philadelphia, Pennsylvania, 19104, United States
Local Institution - 0009

Boston, Massachusetts, 02215, United States
Local Institution - 0011

Ann Arbor, Michigan, 48109, United States
Local Institution - 0012

Los Angeles, California, 90095, United States
Local Institution - 0014

Hackensack, New Jersey, 07601, United States
Local Institution - 0015

Boston, Massachusetts, 02215, United States
Local Institution - 0017

Aurora, Colorado, 80045, United States
Local Institution - 0018

Westwood, Kansas, 66205, United States
Local Institution - 0019

Indianapolis, Indiana, 46202, United States
Local Institution - 0023

Orlando, Florida, 32804, United States
Local Institution - 0028

Columbus, Ohio, 43210, United States
Local Institution - 0033

Omaha, Nebraska, 68130, United States
Local Institution - 0035

Clovis, California, 93611, United States
Local Institution - 0037

Skokie, Illinois, 60077, United States
Local Institution - 0039

Athens, 11528, Greece
Local Institution - 0040

Poznan, 61-848, Poland
Local Institution - 0042

Wroclaw, 50-367, Poland
Local Institution - 0043

Poitiers, Vienne, 86021, France
Local Institution - 0044

Nantes, 44000, France
Local Institution - 0045

Ghent, 9000, Belgium
Local Institution - 0047

Sint-Niklaas, 9100, Belgium
Local Institution - 0049

Warsaw, 02-776, Poland
Local Institution - 013

New Haven, Connecticut, 06520, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
OHSU Center for Hematologic Malignancies

Portland, Oregon, 97239, United States
The Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
University Of Michigan Health System

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

HODGKIN LYMPHOMA MULTIPLE MYELOMA NON-HODGKIN'S LYMPHOMA